Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise…
Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s
Dr Reddy’s receives positive CHMP opinion for biosimilar Rituximab candidate in European markets
Dr Reddy's Rituximab biosimilar DRL_RI (ITUXREDI) progresses towards European approval with EMA CHMP endorsement
Alvotech and Dr Reddy’s collaborate on biosimilar AVT03
Dr Reddy’s gets exclusive commercialisation rights of denosumab in the US as well as semi-exclusive rights in Europe and UK
Industry growth weakens sharply in Mar’24
For the 12 months through Mar’24, IPM grew 7.6 per cent YoY and prices/volume/new launches increased by 4.0 per cent/0.7 per…
Dr Reddy’s rolls out Nerivio, drug-free non-invasive migraine management device, in India
Nerivio is the first and only USFDA approved device to use Remote Electrical Neuromodulation (REN) to prevent and treat migraine
USFDA completes GMP inspection of Dr Reddy’s Hyderabad API manufacturing facility
The inspection closed with zero observations
Dr Reddy’s ropes in Sonu Sood as brand ambassador for Rebalanz VITORS
Rebalanz VITORS is a ready-to-serve fruit beverage with essential electrolytes and minerals to help replenish essential salts in…
Express Pharma-Nutrify Today Boardroom series to be launched this February
The Express Pharma- Nutrify Today Boardroom series, to be held in various cities of India through 2023, is an endeavour to…
Dr Reddy’s Lab Q3 results: Consolidated net profit up 77 per cent at Rs 1,247 crore
The drug firm had reported a net profit of Rs 706 crore in the October-December period of the previous fiscal.
Dr Reddy’s completes clinical studies of rituximab biosimilar for filing in US and Europe
Dr Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets